NFKB1 and COVID-19: Imatinib is one of the drugs that reinforce the endothelial barrier and mitigate alveolar inflammatory responses through NFkB mediated chemotaxis in several models of acute lung injury and may therefore prevent clinical progression of COVID-19 [29].